Title: Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
Authors: Coosemans, An ×
Wölfl, Matthias
Berneman, Zwi N
Van Tendeloo, Viggo
Vergote, Ignace
Amant, Frédéric
Van Gool, Stefaan #
Issue Date: Sep-2010
Publisher: Potamitis Press
Series Title: Anticancer Research vol:30 issue:9 pages:3709-14
Abstract: BACKGROUND: Wilms' tumour gene 1 (WT1), a highly ranked immunotherapeutic target, is expressed in uterine cancer and therefore WT1 immunotherapy may present an attractive treatment option. PATIENT AND METHODS: An HLA-A2.1-positive 46-year-old woman with end-stage serous endometrial cancer received 4 weekly injections of WT1-RNA-loaded dendritic cells. Response was measured clinically (CT scan), biochemically (CA125) and immunologically (WT1-specific T cells). RESULTS: The patient showed WT1 positivity in 10% of tumour cells and diffusely in the intratumoural endothelial cells of the recurrent disease. After 2 injections, CA125 started to decrease and WT1-specific T-cells increased 2.5-fold. The treatment was feasible and there were no treatment-related side-effects. However, the patient, suffering from diffuse disease which became progressive again, died 8 months later. CONCLUSION: This is the first patient with a WT1-positive endometrial carcinoma, to receive immunotherapy with WT1-RNA-loaded dendritic cells, resulting in a vaccine-specific T cell response.
ISSN: 0250-7005
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
Pediatric Hematology & Oncology Section (-)
Laboratory of Pediatric Immunology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Coosemans_first uterine cancer patient_ANTICANCER RESEARCH 2010.pdf Published 221KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science